


MYMEE

Introducing a new standard of care for non-responders to autoimmune biologics & biosimilars


- Autoimmune drugs cost over \$100B annually in the US, and biologics make up 54% of specialty Rx growth.
- On average, 40% of rheumatic patients are non-responders and over 70% do not sustain remission in the real world.
- Mymee provides the 1st evidence-based, coach-led, personalized trial & care platform for patients unable to control autoimmune disease flares with prescription drugs.
- Statistically significant improvements in all 10 HRQoL PROMIS® domains and >40% mean reduction in 59 patient-reported symptoms; the more severe, the greater the improvement^{1, 2}
- Avg. annual Rx savings of >\$11k/patient on biologics, with 83% completion rate.³



Sources: 1) Peer-reviewed study of personalized trials in autoimmune pop., Rheumatic & Musculoskeletal Open Journal May 2023. 2) Symptoms-59 survey, weighted mean change in 182 personalized trials. 3) Payer value study among plan members on autoimmune biologics 2020-22 (list prices before rebates).

Mymee's proprietary personalized trial & care platform replaces trial & error for patients who can no longer control flares with Rx.

Need for ongoing care depends on level of sensitivity to the exposome & whether Rx can be optimized to reduce vulnerability to flares.



MYMEE

transforming autoimmune care through personalized trials™

Key milestones & awards as an autoimmune industry pioneer

- ✓ Payer-audited, value-based, real world evidence with biologic non-responders
- ✓ SOC2 Certified, HIPAA Compliant, NPS 86, available nationwide
- ✓ KOL advisors, investors, leadership
- ✓ 1st board certified, dedicated autoimmune health coach training program
- ✓ Acquired Breakthrough Health (#1 MS App Emilyn, team from ResearchGate)
- ✓ Preferred Partner of Mt. Sinai Hospital for Long COVID since 2020

- 🏆 Peer reviewed publications in: Rheumatic & Musculoskeletal Disease Open Journal ('23), IFM Conf ('23 & '20), ACR Conf ('22), JMIR ('20), IEEE conf ('20)
- 🏆 Top 100 NY Healthcare Startups 2022 & 2023
- 🏆 Health 2.0 Outstanding Leadership Award, CEO & Founder 2022
- 🏆 Juniper Networks Awards 2022: #1 Most Innovative Precision Medicine Solution
- 🏆 Nominee Prix Galien Award; Digital Health, 2021
- 🏆 Honoree Fast Company World Changing Ideas Awards 2021

Led by experienced executive team and advised by industry key opinion leaders



Founder, CEO, Board
Mette Dyhrberg

Serial entrepreneur, non-responder to biologics, solved her own case, 1st patent in 2013. Chair of Health Tech Hub Copenhagen, Denmark.



Exec Chairperson
Gillian Sandler

Decades as investor, CEO. HC portfolio focused on autoimmune & neuro. Former JPM equity analyst.



CFO/COO, Board
Robert Voreyer

Decades as CFO and corporate finance leader in healthcare tech & agriculture.



CBO, Board
Deborah Fine

Serial CEO & commercialization leader. Diagnostics, consumer, digital health.

Best-in-class team includes specialized tech, product, care delivery, research, data, BD.

Medical and Healthcare Advisory Board members with leadership experience at:



Cleveland Clinic



omada

virta



medidata NOOM



KAISER
PERMANENTE

UCSF

OSCAR

THE INSTITUTE FOR
FUNCTIONAL
MEDICINE®

McKinsey

Google

MYMEE®

transforming autoimmune care through personalized trials™